Summary

The global hemodialysis and peritoneal dialysis market was valued at USD 102.7 billion in 2026 and is expected to reach USD 141.5 billion by 2031, growing at a CAGR of 6.6% during the forecast period. Rising prevalence of chronic kidney disease (CKD) and end-stage renal disease (ESRD), driven by increasing rates of diabetes, hypertension, and aging populations worldwide, is the primary force behind market expansion. Growing adoption of home-based dialysis therapies, supported by cost-containment policies in healthcare systems and payer reimbursement frameworks such as the Centers for Medicare & Medicaid Services (CMS) in the US, is broadening the patient base for both home hemodialysis and peritoneal dialysis. Expanding dialysis infrastructure in emerging markets across Asia Pacific, Latin America, and the Middle East and Africa is further adding to global patient volumes. High treatment costs and poor reimbursement for home hemodialysis in several markets outside North America remain constraints on faster adoption of home-based modalities.

“The HD access products subsegment is expected to register the highest CAGR among HD consumables during the forecast period.”
Among the HD consumables and supplies segments, HD access products are projected to grow at the highest CAGR during the forecast period. Vascular access is a prerequisite for every hemodialysis session, and the structural demand it creates is consistent across care settings. Clinical guidelines from the National Kidney Foundation's KDOQI protocols, which prioritize arteriovenous fistula creation as the preferred access method, are driving procedure volumes and associated product consumption. The increasing use of tunneled hemodialysis catheters as a bridge to permanent access, the expanding patient population requiring long-term access management, and growing demand for single-use access needles and securement products are all contributing to this segment's growth. Dialyzers, the second-fastest-growing subsegment, are also benefiting from rising clinical adoption of high-flux and medium-cut-off membrane technologies that improve middle-molecule clearance relative to standard membranes.
“Hospitals accounted for the largest share of the global hemodialysis and peritoneal dialysis market in 2025.”
By end user, hospitals held the largest share of the global hemodialysis and peritoneal dialysis market in 2025. Hospital-based dialysis units manage the full clinical complexity of the ESRD and AKI patient population, including newly diagnosed patients, those with significant comorbidities, and critical care patients requiring continuous renal replacement therapy. The concentration of specialized nephrology staff, dialysis equipment, and emergency infrastructure within hospital settings makes them the default point of care for patients initiating treatment. Independent dialysis centers collectively represent the largest channel but are distributed across a fragmented operator landscape, while hospitals manage a disproportionate share of high-acuity and newly incident patients. Home care settings are growing at the fastest rate among end users, driven by cost pressures in the healthcare system and the expansion of home dialysis program infrastructure.

“North America accounted for the largest share of the global hemodialysis and peritoneal dialysis market in 2025, while Asia Pacific is expected to register the highest CAGR during the forecast period.”
North America accounted for the largest share of the global hemodialysis and peritoneal dialysis market in 2025. The US is the primary driver within this region, supported by a large and structurally growing ESRD patient population of more than 808,000 individuals, according to the United States Renal Data System 2023 Annual Data Report. A mature reimbursement framework under the Medicare ESRD Prospective Payment System, which covers dialysis services at a finalized base rate of USD 281.71 per treatment for calendar year 2026, provides consistent revenue visibility for both product suppliers and service operators. The region is also home to a concentrated network of dialysis facilities, with approximately 7,600 CMS-recognized ESRD centers and major global industry participants. Asia Pacific is the fastest-growing regional market. China and India are the primary growth engines, with government-backed universal CKD coverage programs and subsidized dialysis access schemes accelerating patient enrollment at dialysis centers in both countries.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the hemodialysis and peritoneal dialysis market.
▪ By Company Type: Tier 1 (60%), Tier 2 (30%), and Tier 3 (10%)
▪ By Designation: C-level Executives (30%), Directors (50%), and Other Designations (20%)
▪ By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and the Middle East & Africa (5%)

Fresenius Medical Care (Germany), Vantive (US), B. Braun (Germany), Nipro Corporation (Japan), Nikkiso Co., Ltd. (Japan), DaVita Inc. (US), Asahi Kasei Medical Co., Ltd. (Japan), Toray Medical Co., Ltd. (Japan), JMS Co., Ltd. (Japan), Outset Medical (US), and Rockwell Medical (US) are some of the key players in the global hemodialysis and peritoneal dialysis market.
Study Coverage: This research report categorizes the global hemodialysis and peritoneal dialysis market by product and service (hemodialysis market and peritoneal dialysis market), HD product & service (HD machines, HD consumables & supplies, and HD services), HD machine type (center-use HD machines and home-use HD machines), HD consumables type (dialyzers, bloodlines sets & tubes, hemodialysis concentrates/dialysates, HD access products, and others), HD service type (in-center hemodialysis services and home hemodialysis (HHD) services), PD product & service (PD concentrates/dialysates, PD machines, PD catheters, PD transfer sets, other PD products, and PD services), HD modality (conventional long-term hemodialysis, short daily hemodialysis, and nocturnal hemodialysis), PD modality [continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD)], disease indication (end-stage renal disease (ESRD), acute kidney injury (AKI), and others), end user (hospitals, independent dialysis centers, home care settings, and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The report provides detailed information on the key factors driving growth in the global hemodialysis and peritoneal dialysis markets.
Key Benefits of Buying this Report
▪ Analysis of Key Drivers, Restraints, Opportunities, and Challenges: Gain insights into the principal factors shaping the global hemodialysis and peritoneal dialysis market, including rising CKD and ESRD prevalence, expanding home dialysis adoption, favorable reimbursement policies, high treatment costs, poor home HD reimbursement in select markets, digital health integration opportunities, and patient compliance challenges.
▪ Market Development: Understand current and projected market sizes across all product, service, modality, disease indication, end-user, and regional segments from 2024 to 2031, with base year data for 2025 and a complete historical series from 2024.
▪ Market Diversification: Identify high-growth pockets including HD access products, home hemodialysis services, home care settings, and the Asia Pacific regional market, along with country-level breakdowns for 20+ markets.
▪ Competitive Assessment: Evaluate the competitive positioning of key players including Fresenius Medical Care, Vantive, B. Braun, Nipro Corporation, Nikkiso Co., Ltd., DaVita Inc., Asahi Kasei Medical Co., Ltd., Toray Medical Co., Ltd., JMS Co., Ltd., Outset Medical, and Rockwell Medical, with analysis of their product portfolios, strategies, and recent commercial developments.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 43
1.1 STUDY OBJECTIVES 43
1.2 MARKET DEFINITION 43
1.3 MARKET SCOPE 43
1.3.1 MARKET SEGMENTATION 44
1.4 INCLUSIONS AND EXCLUSIONS 45
1.4.1 YEARS CONSIDERED 46
1.4.2 CURRENCY CONSIDERED 47
1.5 STAKEHOLDERS 47
1.6 LIMITATIONS 47
1.7 SUMMARY OF CHANGES 48
2 EXECUTIVE SUMMARY 49
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 49
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 50
2.3 DISRUPTIVE TRENDS IN HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET 51
2.4 HIGH-GROWTH SEGMENTS 52
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 53
3 PREMIUM INSIGHTS 55
3.1 HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET OVERVIEW 55
3.2 ASIA PACIFIC: HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET, BY END USER AND COUNTRY (2025) 56
3.3 HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET: COUNTRY/REGION 57
4 MARKET OVERVIEW 58
4.1 INTRODUCTION 58
4.2 MARKET DYNAMICS 58
4.2.1 DRIVERS 59
4.2.1.1 Rising prevalence of chronic kidney disease and end-stage renal disease 59
4.2.1.2 Increasing aging population susceptible to kidney disorders 60
4.2.1.3 Growing prevalence of diabetes and hypertension 61
4.2.1.4 Continuous technological advancements in dialysis machines and consumables 62
4.2.2 RESTRAINTS 63
4.2.2.1 High cost of dialysis treatment and infrastructure 63
4.2.2.2 Frequent product recalls and quality compliance issues 64
4.2.3 OPPORTUNITIES 65
4.2.3.1 Expansion of dialysis centers and renal care infrastructure 65
4.2.3.2 Investments in healthcare infrastructure in emerging markets 66
4.2.4 CHALLENGES 67
4.2.4.1 Shortage of nephrologists and trained dialysis professionals 67
4.2.4.2 Risk of dialysis-related infections and complications 67
4.3 UNMET NEEDS AND WHITE SPACES 68
4.3.1 UNMET NEEDS IN HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET 68
4.3.2 WHITE SPACE OPPORTUNITIES 69
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 70
4.4.1 INTERCONNECTED MARKETS 70
4.4.2 CROSS-SECTOR OPPORTUNITIES 71
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 71
4.5.1 STRATEGIC MOVES IN HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET 71
5 INDUSTRY TRENDS 73
5.1 PORTER’S FIVE FORCES ANALYSIS 73
5.1.1 THREAT OF NEW ENTRANTS 74
5.1.2 THREAT OF SUBSTITUTES 75
5.1.3 BARGAINING POWER OF SUPPLIERS 75
5.1.4 BARGAINING POWER OF BUYERS 75
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 75
5.2 MACROECONOMIC INDICATORS 76
5.2.1 INTRODUCTION 76
5.2.2 GDP TRENDS AND FORECAST 76
5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 77
5.2.4 TRENDS IN GLOBAL MEDICAL DEVICE INDUSTRY 77
5.3 SUPPLY CHAIN ANALYSIS 78
5.4 VALUE CHAIN ANALYSIS 79
5.5 ECOSYSTEM ANALYSIS 80
5.5.1 MANUFACTURERS 81
5.5.2 END USERS 82
5.5.3 REGULATORY BODIES 82
5.6 PRICING ANALYSIS 83
5.7 TRADE ANALYSIS 87
5.7.1 IMPORT DATA (HS CODE 9018) 87
5.7.2 EXPORT DATA FOR (HS CODE 9018) 88
5.8 REIMBURSEMENT SCENARIO 88
5.9 KEY CONFERENCES AND EVENTS, 2026–2027 89
5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 90
5.11 INVESTMENT AND FUNDING SCENARIO 90
5.12 CASE STUDY ANALYSIS 91
5.13 IMPACT OF 2025 US TARIFF - HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET 93
5.13.1 INTRODUCTION 93
5.13.2 KEY TARIFF RATES 94
5.13.3 PRICE IMPACT ANALYSIS 94
5.13.4 IMPACT ON COUNTRIES/REGIONS 95
5.13.5 IMPACT ON END-USE SEGMENTS 96
5.13.5.1 Hospitals 96
5.13.5.2 Independent dialysis centers 96
5.13.5.3 Home care settings 97
5.13.5.4 Other end users 97
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 98
6.1 TECHNOLOGY ANALYSIS 98
6.1.1 KEY EMERGING TECHNOLOGIES 98
6.1.1.1 High-volume hemodiafiltration (HDF) 98
6.1.1.2 Intelligent home dialysis platforms 98
6.1.2 COMPLEMENTARY TECHNOLOGIES 98
6.1.2.1 Remote patient management platforms 98
6.1.2.2 Advanced dialyzer membrane technology 98
6.1.3 ADJACENT TECHNOLOGIES 99
6.1.3.1 Portable & wearable artificial kidney technologies 99
6.2 TECHNOLOGY/PRODUCT ROADMAP 99
6.2.1 NEAR TERM (2025–2027) 99
6.2.2 MID-TERM (2028–2030) 99
6.2.3 LONG TERM (2030+) 99
6.3 PATENT ANALYSIS 100
6.3.1 JURISDICTION AND TOP APPLICANT ANALYSIS 100
6.4 FUTURE APPLICATIONS 102
6.4.1 AI-ASSISTED TREATMENT PLANNING AND THERAPY OPTIMIZATION 103
6.4.2 PERSONALIZED DIALYSIS THERAPY 103
6.4.3 CONNECTED DIALYSIS WORKFLOWS AND DIGITAL INTEGRATION 103
6.5 IMPACT OF AI/GEN AI ON HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET 103
6.5.1 INTRODUCTION 103
6.5.2 MARKET POTENTIAL OF AI IN HEMODIALYSIS AND PERITONEAL DIALYSIS 104
6.5.3 AI USE CASES 104
6.5.4 KEY COMPANIES IMPLEMENTING AI 105
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 107
7.1 REGULATORY LANDSCAPE 107
7.1.1 REGULATORY FRAMEWORK 107
7.1.1.1 North America 107
7.1.1.2 Europe 107
7.1.1.3 Asia Pacific 108
7.1.1.4 Latin America 108
7.1.1.5 Middle East & Africa 108
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 109
7.1.3 INDUSTRY STANDARDS 111
7.2 SUSTAINABILITY INITIATIVES 112
7.2.1 REDUCING MEDICAL WASTE & USE OF LOWER-IMPACT MATERIALS AND PACKAGING 112
7.2.2 WATER, ENERGY, & RESOURCE EFFICIENCY 112
7.2.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 112
8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR 114
8.1 DECISION-MAKING PROCESS 114
8.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR CRITERIA 114
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 115
8.2.2 BUYING CRITERIA 116
8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES 116
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 117
8.5 MARKET PROFITABILITY 118
9 HEMODIALYSIS MARKET, BY PRODUCT & SERVICE 119
9.1 INTRODUCTION 120
9.2 HEMODIALYSIS SERVICES 120
9.2.1 IN—CENTER HEMODIALYSIS SERVICES 122
9.2.1.1 Growing geriatric population and increasing government healthcare expenditure to drive segment 122
9.2.2 HOME HEMODIALYSIS SERVICES 123
9.2.2.1 Poor reimbursement scenario and high treatment costs to limit market growth 123
9.3 HEMODIALYSIS PRODUCTS 125
9.3.1 HEMODIALYSIS MACHINES 126
9.3.1.1 Center-use hemodialysis machines 128
9.3.1.1.1 Rising number of renal care centers to aid segment growth 128
9.3.1.1.2 Volume analysis of center-use hemodialysis machines, 2024–2031 (ten thousand units) 130
9.3.1.2 Home-use hemodialysis machines 130
9.3.1.2.1 Lesser hospital stays and better clinical outcomes to propel segment growth 130
9.3.1.2.2 Volume analysis of home-use hemodialysis machines, 2024–2031 (ten thousand units) 132
9.3.2 HEMODIALYSIS CONSUMABLES & SUPPLIES 132
9.3.2.1 Dialyzers 134
9.3.2.1.1 Dialyzers market, by material 135
9.3.2.1.1.1 Synthetic dialyzers 136
9.3.2.1.1.1.1 High physical strength and increased chemical resistance to drive segment 136
9.3.2.1.1.1.2 Volume analysis of synthetic dialyzers,
2024-2031 (Ten Thousand Units) 138
9.3.2.1.1.2 Cellulose-based dialyzers 138
9.3.2.1.1.2.1 Affordability and high biocompatibility to support segment growth 138
9.3.2.1.1.2.2 volume analysis of cellulose-based dialyzers,
2024-2031 (ten thousand units) 140
9.3.2.1.2 Dialyzers market, by flux 140
9.3.2.1.2.1 High-flux dialyzers 141
9.3.2.1.2.1.1 High-flux dialyzers to command larger market share during forecast period 141
9.3.2.1.2.1.2 Volume analysis of high-flux dialyzers,
2024-2031 (Ten Thousand units) 143
9.3.2.1.2.2 Low-flux dialyzers 143
9.3.2.1.2.2.1 Ability to filter small toxin particles to propel segment growth 143
9.3.2.1.2.2.2 Volume analysis of low-flux dialyzers,
2024-2031 (Ten Thousand Units) 145
9.3.2.2 Bloodline sets and tubes 145
9.3.2.2.1 High pricing and reduced rate of reuse to limit market expansion 145
9.3.2.2.2 Volume analysis of bloodline sets and tubes,
2024-2031 (Ten Thousand Units) 147
9.3.2.3 Concentrates/Dialysates 147
9.3.2.3.1 Alkaline concentrates 149
9.3.2.3.1.1 Growing consumption before dialysis to boost segment growth 149
9.3.2.3.1.2 Volume analysis of alkaline concentrates,
2024-2031 (Ten Thousand Units) 151
9.3.2.3.2 Acidic concentrates 151
9.3.2.3.2.1 Increased number of side effects to limit segment growth 151
9.3.2.3.2.2 Volume analysis of acidic concentrates,
2024-2031 (Ten Thousand Units) 153
9.3.2.4 Access products 153
9.3.2.4.1 AV fistula needles 155
9.3.2.4.1.1 Better blood flow and lower infection risk to aid segment growth 155
9.3.2.4.2 AV grafts 157
9.3.2.4.2.1 Increased number of patients requiring long-term dialysis to support segment growth 157
9.3.2.4.3 Central venous catheters 158
9.3.2.4.3.1 Increased use in temporary vascular access for short-term dialysis to boost segment growth 158
9.3.2.5 Other hemodialysis consumables & supplies 161
9.3.2.5.1 Volume analysis of other hemodialysis consumables,
2024-2031 (Ten Thousand Units) 163
9.4 HEMODIALYSIS MARKET, BY MODALITY 163
9.4.1 CONVENTIONAL HEMODIALYSIS 164
9.4.1.1 Technological advancements and rising number of dialysis centers to drive segment 164
9.4.2 SHORT DAILY HEMODIALYSIS 165
9.4.2.1 Improved blood pressure control and better calcium-phosphorus balance to augment segment growth 165
9.4.3 NOCTURNAL HEMODIALYSIS 167
9.4.3.1 Lower procedure costs to aid segment growth 167
9.5 HEMODIALYSIS WATER TREATMENT SYSTEMS MARKET, BY TYPE 168
9.5.1 CENTRAL WATER DISINFECTION SYSTEMS 170
9.5.1.1 Cost-effectiveness and easy maintenance to drive market 170
9.5.1.1.1 Volume analysis of central water disinfection systems, 2024-2031 (Ten Thousand Units) 172
9.5.2 PORTABLE WATER DISINFECTION SYSTEMS 172
9.5.2.1 User-friendly operations and improved microbiological purity to support segment growth 172
9.5.2.1.1 Volume analysis of portable water disinfection systems, 2024-2031 (Ten Thousand Units) 174
10 PERITONEAL DIALYSIS MARKET, BY PRODUCT & SERVICE 175
10.1 INTRODUCTION 176
10.2 PERITONEAL DIALYSIS PRODUCTS 177
10.2.1 PERITONEAL DIALYSIS CONCENTRATES/DIALYSATES 179
10.2.1.1 High demand for concentrates to boost segment growth 179
10.2.1.1.1 Volume analysis of peritoneal dialysis concentrates/ dialysates, 2024-2031 (Ten Thousand Units) 181
10.2.2 PERITONEAL DIALYSIS MACHINES 181
10.2.2.1 Rising prevalence of chronic diseases in emerging economies to boost adoption 181
10.2.2.1.1 Volume analysis of peritoneal dialysis machines,
2024-2031 (Ten Thousand Units) 183
10.2.3 PERITONEAL DIALYSIS CATHETERS 183
10.2.3.1 Favorable reimbursement policies to support market growth 183
10.2.3.1.1 Volume analysis of peritoneal dialysis catheters,
2024-2031 (Ten Thousand Units) 185
10.2.4 PERITONEAL DIALYSIS TRANSFER SETS 185
10.2.4.1 Increasing number of patients in emerging economies to aid market growth 185
10.2.4.1.1 Volume analysis of peritoneal dialysis transfer sets,
2024-2031 (Ten Thousand Units) 187
10.2.5 OTHER PERITONEAL DIALYSIS PRODUCTS 187
10.2.5.1 Volume analysis of other peritoneal dialysis products,
2024-2031 (Ten Thousand Units) 189
10.3 PERITONEAL DIALYSIS SERVICES 189
10.3.1 BETTER PRIVACY AND INCREASED COMFORT OF AT-HOME DIALYSIS TREATMENT TO DRIVE MARKET 189
10.4 PERITONEAL DIALYSIS MARKET, BY MODALITY 191
10.4.1 CONTINUOUS AMBULATORY PERITONEAL DIALYSIS 191
10.4.1.1 Superior clearance of high-molecular-weight substances to drive market 191
10.4.2 AUTOMATED PERITONEAL DIALYSIS 192
10.4.2.1 Risk of rapid decline in residual renal functions to limit adoption 192
11 HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET, BY APPLICATION 194
11.1 INTRODUCTION 195
11.2 END-STAGE RENAL DISEASE 195
11.2.1 RISING GERIATRIC POPULATION AND INCREASING PREVALENCE OF DIABETES TO DRIVE MARKET 195
11.3 ACUTE KIDNEY INJURY 196
11.3.1 INCREASING NUMBER OF HOSPITALIZATIONS TO PROPEL MARKET GROWTH 196
11.4 OTHER INDICATIONS 198
12 HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET, BY END USER 199
12.1 INTRODUCTION 200
12.2 HOSPITALS 200
12.2.1 IMPROVED FACILITIES AND INCREASED GOVERNMENT SUPPORT TO DRIVE MARKET 200
12.3 INDEPENDENT DIALYSIS CENTERS 201
12.3.1 INCREASED DEMAND FOR ADVANCED DIALYSIS AND END-STAGE RENAL DISEASE TREATMENTS TO PROPEL MARKET GROWTH 201
12.4 HOME CARE SETTINGS 203
12.4.1 LOWER COST AND SHORTER HOSPITAL STAYS TO AID MARKET GROWTH 203
12.5 OTHER END USERS 204
13 HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET, BY REGION 206
13.1 INTRODUCTION 207
13.2 NORTH AMERICA 207
13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 208
13.2.2 NORTH AMERICA: VOLUME ANALYSIS OF HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET, BY TYPE, 2024–2031 210
13.2.3 US 217
13.2.3.1 US to dominate North American market during study period 217
13.2.4 CANADA 223
13.2.4.1 Shortage of dialysis facilities and increased treatment cost to restrain market expansion 223
13.3 EUROPE 230
13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 230
13.3.2 EUROPE: VOLUME ANALYSIS OF HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET, BY TYPE, 2024–2031 231
13.3.3 GERMANY 238
13.3.3.1 Rising number of end-stage renal disease patients to boost market growth 238
13.3.4 UK 244
13.3.4.1 Expanding home dialysis programs and strong NHS support to drive market 244
13.3.5 FRANCE 250
13.3.5.1 Strong reimbursement framework and growing home dialysis adoption to fuel market 250
13.3.6 ITALY 257
13.3.6.1 Universal healthcare coverage and rising CKD burden to support market growth 257
13.3.7 SPAIN 263
13.3.7.1 Increasing CKD prevalence and expanding renal care infrastructure to drive market 263
13.3.8 REST OF EUROPE 269
13.4 ASIA PACIFIC 275
13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 276
13.4.2 ASIA PACIFIC: VOLUME ANALYSIS OF HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET, BY TYPE, 2024–2031 277
13.4.3 CHINA 284
13.4.3.1 Expanding dialysis infrastructure and large CKD patient base to drive market 284
13.4.4 JAPAN 290
13.4.4.1 Advanced dialysis infrastructure and universal reimbursement to support market growth 290
13.4.5 INDIA 296
13.4.5.1 Government-led dialysis expansion and rising CKD burden to fuel market 296
13.4.6 AUSTRALIA 303
13.4.6.1 High adoption of home dialysis and strong healthcare system to support market growth 303
13.4.7 SOUTH KOREA 310
13.4.7.1 Growing CKD burden and expanding renal care services to drive market 310
13.4.8 REST OF ASIA PACIFIC 317
13.5 LATIN AMERICA 323
13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 324
13.5.2 LATIN AMERICA: VOLUME ANALYSIS OF HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET, BY TYPE, 2024–2031 325
13.5.3 BRAZIL 332
13.5.3.1 Large dialysis patient base and expanding renal care infrastructure to drive market 332
13.5.4 MEXICO 338
13.5.4.1 Healthcare reforms and expanding access to dialysis to support market growth 338
13.5.5 REST OF LATIN AMERICA 345
13.6 MIDDLE EAST & AFRICA 351
13.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 351
13.6.2 MIDDLE EAST & AFRICA: VOLUME ANALYSIS OF HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET, BY TYPE, 2024–2031 352
13.6.3 GCC COUNTRIES 359
13.6.3.1 Kingdom of Saudi Arabia (KSA) 366
13.6.3.1.1 Saudi Vision 2030 and expanding dialysis infrastructure to drive market 366
13.6.3.2 United Arab Emirates (UAE) 373
13.6.3.2.1 Growing investments in renal care and rising CKD burden to support market growth 373
13.6.3.3 Other GCC countries 380
13.6.4 REST OF MIDDLE EAST & AFRICA 387
14 COMPETITIVE LANDSCAPE 394
14.1 OVERVIEW 394
14.2 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN, 2023–JUNE 2026 394
14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET 395
14.3 REVENUE ANALYSIS 396
14.4 MARKET SHARE ANALYSIS 397
14.4.1 GLOBAL HEMODIALYSIS MARKET SHARE ANALYSIS, 2025 397
14.4.1.1 US hemodialysis market share analysis, 2025 398
14.4.1.2 Europe hemodialysis market share analysis, 2025 398
14.4.2 GLOBAL PERITONEAL DIALYSIS MARKET SHARE ANALYSIS, 2025 399
14.4.2.1 US peritoneal dialysis market share analysis, 2025 400
14.4.2.2 Europe peritoneal dialysis market share analysis, 2025 401
14.5 BRAND/PRODUCT COMPARISON 404
14.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 404
14.6.1 STARS 404
14.6.2 EMERGING LEADERS 405
14.6.3 PERVASIVE PLAYERS 405
14.6.4 PARTICIPANTS 405
14.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 407
14.6.5.1 Company footprint 407
14.6.5.2 Region footprint 408
14.6.5.3 Hemodialysis product & service footprint 409
14.6.5.4 Hemodialysis modality footprint 410
14.6.5.5 Hemodialysis water treatment system type footprint 410
14.6.5.6 Peritoneal dialysis product & service footprint 411
14.6.5.7 Peritoneal dialysis modality footprint 412
14.6.5.8 Hemodialysis and peritoneal dialysis application footprint 413
14.6.5.9 Hemodialysis and peritoneal dialysis end user footprint 414
14.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 414
14.7.1 PROGRESSIVE COMPANIES 414
14.7.2 RESPONSIVE COMPANIES 415
14.7.3 DYNAMIC COMPANIES 415
14.7.4 STARTING BLOCKS 415
14.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 416
14.7.5.1 Detailed list of key startups/SMEs 416
14.7.5.2 Competitive benchmarking of key startups/SMEs 417
14.8 COMPANY VALUATION AND FINANCIAL METRICS 418
14.8.1 COMPANY VALUATION 418
14.8.2 FINANCIAL METRICS 418
14.9 COMPETITIVE SCENARIO 419
14.9.1 PRODUCT LAUNCHES & APPROVALS 419
14.9.2 DEALS 420
14.9.3 EXPANSIONS 421
14.9.4 OTHER DEVELOPMENTS 421
15 COMPANY PROFILES 422
15.1 KEY PLAYERS 422
15.1.1 FRESENIUS MEDICAL CARE AG 422
15.1.1.1 Business overview 422
15.1.1.2 Products/Solutions/Services offered 423
15.1.1.3 Recent developments 427
15.1.1.3.1 Product launches & approvals 427
15.1.1.3.2 Deals 428
15.1.1.3.3 Expansions 428
15.1.1.3.4 Other developments 428
15.1.1.4 MnM view 429
15.1.1.4.1 Key strengths 429
15.1.1.4.2 Strategic choices 429
15.1.1.4.3 Weaknesses & competitive threats 429
15.1.2 DAVITA INC. 430
15.1.2.1 Business overview 430
15.1.2.2 Products/Solutions/Services offered 431
15.1.2.3 Recent developments 431
15.1.2.3.1 Deals 431
15.1.2.4 MnM view 432
15.1.2.4.1 Key strengths 432
15.1.2.4.2 Strategic choices 432
15.1.2.4.3 Weaknesses & competitive threats 432
15.1.3 VANTIVE 433
15.1.3.1 Business overview 433
15.1.3.2 Products/Solutions/Services offered 433
15.1.3.3 Recent developments 437
15.1.3.3.1 Product launches & approvals 437
15.1.3.3.2 Deals 437
15.1.3.3.3 Expansions 437
15.1.3.3.4 Other developments 438
15.1.3.4 MnM view 438
15.1.3.4.1 Key strengths 438
15.1.3.4.2 Strategic choices 438
15.1.3.4.3 Weaknesses & competitive threats 438
15.1.4 U.S. RENAL CARE, INC. 439
15.1.4.1 Business overview 439
15.1.4.2 Products/Solutions/Services offered 439
15.1.4.3 MnM view 440
15.1.4.3.1 Key strengths 440
15.1.4.3.2 Strategic choices 440
15.1.4.3.3 Weaknesses & competitive threats 440
15.1.5 B. BRAUN SE 441
15.1.5.1 Business overview 441
15.1.5.2 Products/Solutions/Services offered 442
15.1.5.3 Recent developments 445
15.1.5.3.1 Expansions 445
15.1.5.4 MnM view 445
15.1.5.4.1 Key strengths 445
15.1.5.4.2 Strategic choices 445
15.1.5.4.3 Weaknesses & competitive threats 446
15.1.6 NIPRO CORPORATION 447
15.1.6.1 Business overview 447
15.1.6.2 Products/Solutions/Services offered 448
15.1.6.3 Recent developments 451
15.1.6.3.1 Product launches & approvals 451
15.1.6.3.2 Deals 451
15.1.6.3.3 Expansions 452
15.1.7 DIAVERUM AB 453
15.1.7.1 Business overview 453
15.1.7.2 Products/Solutions/Services offered 453
15.1.7.3 Recent developments 454
15.1.7.3.1 Deals 454
15.1.7.3.2 Expansions 455
15.1.8 ASAHI KASEI MEDICAL CO., LTD. 456
15.1.8.1 Business overview 456
15.1.8.2 Products/Solutions/Services offered 456
15.1.8.3 Recent developments 457
15.1.8.3.1 Deals 457
15.1.8.3.2 Other developments 457
15.1.9 TORAY INDUSTRIES, INC. 458
15.1.9.1 Business overview 458
15.1.9.2 Products/Solutions/Services offered 459
15.1.10 NIKKISO CO., LTD. 461
15.1.10.1 Business overview 461
15.1.10.2 Products/Solutions/Services offered 462
15.1.10.3 Recent developments 463
15.1.10.3.1 Product launches & approvals 463
15.1.10.3.2 Deals 464
15.1.11 MOZARC MEDICAL 465
15.1.11.1 Business overview 465
15.1.11.2 Products/Solutions/Services offered 465
15.1.11.3 Recent developments 467
15.1.11.3.1 Deals 467
15.1.12 BD 468
15.1.12.1 Business overview 468
15.1.12.2 Products/Solutions/Services offered 469
15.1.12.3 Recent developments 470
15.1.12.3.1 Deals 470
15.1.12.3.2 Expansions 470
15.1.13 JMS CO., LTD. 471
15.1.13.1 Business overview 471
15.1.13.2 Products/Solutions/Services offered 472
15.1.14 MERIT MEDICAL SYSTEMS 474
15.1.14.1 Business overview 474
15.1.14.2 Products/Solutions/Services offered 475
15.1.14.3 Recent developments 476
15.1.14.3.1 Deals 476
15.1.15 TERUMO CORPORATION 477
15.1.15.1 Business overview 477
15.1.15.2 Products/Solutions/Services offered 478
15.2 OTHER PLAYERS 480
15.2.1 ALLMED MEDICAL PRODUCTS CO., LTD. 480
15.2.2 OUTSET MEDICAL, INC. 481
15.2.3 ROCKWELL MEDICAL, INC. 482
15.2.4 AMERIWATER LLC 483
15.2.5 DIALIFE SA 484
15.2.6 QUANTA DIALYSIS TECHNOLOGIES LTD 485
15.2.7 ISOPURE CORP. 486
15.2.8 POLY MEDICURE LIMITED 487
15.2.9 ATLANTIC BIOMEDICAL 488
15.2.10 AMECATH 489
16 RESEARCH METHODOLOGY 490
16.1 RESEARCH DATA 490
16.1.1 SECONDARY DATA 491
16.1.1.1 Key secondary sources 492
16.1.2 PRIMARY DATA 492
16.1.2.1 Primary sources 493
16.1.2.2 Key data from primary sources 494
16.1.2.3 Key industry insights 494
16.1.2.4 Breakdown of primaries 495
16.2 MARKET SIZE ESTIMATION 496
16.2.1 APPROACH 1: COMPANY REVENUE ANALYSIS APPROACH 497
16.2.2 APPROACH 2: CUSTOMER-BASED MARKET ESTIMATION 499
16.2.3 APPROACH 3: TOP-DOWN APPROACH 499
16.2.4 APPROACH 4: BOTTOM-UP APPROACH 500
16.2.5 APPROACH 4: PRIMARY INTERVIEWS 500
16.2.6 APPROACH 5: DEMAND-SIDE APPROACH 501
16.2.7 APPROACH 6: VOLUME DATA ANALYSIS 502
16.3 DATA TRIANGULATION AND MARKET BREAKDOWN 505
16.4 MARKET SHARE ASSESSMENT 506
16.5 RESEARCH ASSUMPTIONS 506
16.5.1 STUDY ASSUMPTIONS 506
16.5.2 GROWTH RATE ASSUMPTIONS 506
16.6 RISK ASSESSMENT 507
16.7 RESEARCH LIMITATIONS 507
17 APPENDIX 508
17.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 512
17.2 CUSTOMIZATION OPTIONS 514
17.2.1 PRODUCT ANALYSIS 514
17.2.2 COMPANY INFORMATION 514
17.2.3 GEOGRAPHIC ANALYSIS 514
17.3 RELATED REPORTS 514
17.4 AUTHOR DETAILS 515